{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:42:10Z","timestamp":1792633330380,"version":"4.5.0"},"reference-count":110,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Idiopathic inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM), are a diverse group of autoimmune diseases characterized by muscular involvement and extramuscular manifestations. Interstitial lung disease (ILD) has major pulmonary involvement and is associated with increased mortality in PM\/DM\/CADM. The management of PM-\/DM-\/CADM-associated ILD (PM\/DM\/CADM-ILD) requires careful evaluation of the disease severity and clinical subtype, including the ILD forms (acute\/subacute or chronic), because of the substantial heterogeneity of their clinical courses. Recent studies have highlighted the importance of myositis-specific autoantibodies\u2019 status, especially anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl tRNA synthetase (ARS) antibodies, in order to evaluate the clinical phenotypes and treatment of choice for PM\/DM\/CADM-ILD. Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM\/CADM-ILD. Rapidly progressive DM\/CADM-ILD with the anti-MDA5 antibody is the most intractable condition, which requires immediate combined immunosuppressive therapy with GCs, CNIs, and intravenous cyclophosphamide. Additional salvage therapies (rituximab, tofacitinib, and plasma exchange) should be considered for patients with refractory ILD. Patients with anti-ARS antibody-positive ILD respond better to GC treatment, but with frequent recurrence; thus, GCs plus immunosuppressants (TAC, CsA, azathioprine, and mycophenolate mofetil) are often needed in order to achieve favorable long-term disease control. PM\/DM\/CADM-ILD management is still a therapeutic challenge for clinicians, as evidence-based guidelines do not exist to help with management decisions. A few prospective clinical trials have been recently reported regarding the treatment of PM\/DM\/CADM-ILD. Here, the current knowledge on the pharmacologic managements of PM\/DM\/CADM-ILD was mainly reviewed.<\/jats:p>","DOI":"10.3390\/medicina57040347","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T22:03:36Z","timestamp":1617487416000},"page":"347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Management of Myositis-Associated Interstitial Lung Disease"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-1781","authenticated-orcid":false,"given":"Tomoyuki","family":"Fujisawa","sequence":"first","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/rheumatology\/keh723","article-title":"Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis","volume":"44","author":"Kang","year":"2005","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_8","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fujisawa, T., Hozumi, H., Kono, M., Enomoto, N., Hashimoto, D., Nakamura, Y., Inui, N., Yokomura, K., Koshimizu, N., and Toyoshima, M. (2014). Prognostic Factors for Myositis-Associated Interstitial Lung Disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098824"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","article-title":"Interstitial lung diseases associated with amyopathic dermatomyositis","volume":"28","author":"Suda","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study","volume":"26","author":"Ye","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1378\/chest.08-2740","article-title":"Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis","volume":"136","author":"Mukae","year":"2009","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"Yoo","year":"2007","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.rmed.2007.01.023","article-title":"Interstitial lung disease associated with amyopathic dermatomyositis: Review of 18 cases","volume":"101","author":"Ideura","year":"2007","journal-title":"Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: A single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti\u2013Melanoma Differentiation\u2013Associated Gene 5\u2013Positive Dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: A multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Huapaya","year":"2017","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hamaguchi, Y., Fujimoto, M., Matsushita, T., Kaji, K., Komura, K., Hasegawa, M., Kodera, M., Murio, E., Fujikawa, F., and Seishima, M. (2013). Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: Heterogeneity within the syndrome. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060442"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","article-title":"Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases","volume":"55","author":"Fujisawa","year":"2017","journal-title":"Respir. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08916930600622884","article-title":"Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies","volume":"39","author":"Yoshifuji","year":"2006","journal-title":"Autoimmunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis\/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hozumi, H., Enomoto, N., Kono, M., Fujisawa, T., Inui, N., Nakamura, Y., Sumikawa, H., Johkoh, T., Nakashima, R., and Imura, Y. (2015). Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: A retrospective case control study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120313"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2009","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis","volume":"44","author":"Oddis","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients with or Without Specific Autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am. J. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-Melanoma Differentiation-Associated Gene 5 Is Associated with Rapidly Progressive Lung Disease and Poor Survival in US Patients with Amyopathic and Myopathic Dermatomyositis","volume":"68","author":"Oddis","year":"2016","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3899\/jrheum.180825","article-title":"Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody\u2013positive Dermatomyositis-associated Interstitial Lung Disease","volume":"46","author":"Fujisawa","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Castellvi","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/kes012","article-title":"Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/s10165-010-0371-x","article-title":"Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis","volume":"21","author":"Gono","year":"2011","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of Myositis-Related Interstitial Lung Disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2006","journal-title":"Rheumatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Parambil","year":"2013","journal-title":"Respir. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2014","journal-title":"Rheumatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.65.4.403","article-title":"Interstitial Pneumonitis in Association with Polymyositis and Dermatomyositis","volume":"65","author":"Frazier","year":"1974","journal-title":"Chest"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2169\/internalmedicine.37.669","article-title":"Clinical Features of Polymyositis\/Dermatomyositis with Steroid-Resistant Interstitial Lung Disease","volume":"37","author":"Takada","year":"1998","journal-title":"Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: A retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","article-title":"Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia","volume":"30","author":"Kotani","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_59","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Molberg, \u00d8yvind Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review","volume":"45","author":"Doyle","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ge, Y., Li, S., Tian, X., He, L., Lu, X., and Wang, G. (2021). Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin. Rheumatol., 1\u20137.","DOI":"10.1007\/s10067-020-05530-5"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kato, M., Ikeda, K., Kageyama, T., Kasuya, T., Kumagai, T., Furuya, H., Furuta, S., Tamachi, T., Suto, A., and Suzuki, K. (2019). Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis. J. Clin. Rheumatol.","DOI":"10.1097\/00124743-900000000-99084"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in Amyopathic Dermatomyositis\u2013Associated Interstitial Lung Disease","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous Immunoglobulin Therapy for Refractory Interstitial Lung Disease Associated with Polymyositis\/Dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: Remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1183\/09031936.03.00026703","article-title":"Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis","volume":"22","author":"Cottin","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_73","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/CCRPM.S23313","article-title":"Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies","volume":"9s1","author":"Kawasumi","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial Lung Disease in Polymyositis and Dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin. Chest Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","article-title":"Polymyositis\/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants","volume":"38","author":"Takada","year":"2005","journal-title":"Autoimmunity"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/1756-185X.12931","article-title":"Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis","volume":"19","author":"Ueno","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1756-185X.13414","article-title":"Efficacy and safety of oral high-trough level tacrolimus in acute\/subacute interstitial pneumonia with dermatomyositis","volume":"22","author":"Suzuka","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients with Dermatomyositis and Polymyositis","volume":"23","author":"Shimojima","year":"2017","journal-title":"JCR J. Clin. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/s10165-010-0342-2","article-title":"Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis","volume":"21","author":"Nagai","year":"2011","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: A systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2169\/internalmedicine.36.519","article-title":"Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis Responding to Intravenous Cyclophosphamide Pulse Therapy","volume":"36","author":"Shinohara","year":"1997","journal-title":"Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2169\/internalmedicine.38.733","article-title":"Pulse Intravenous Cyclophosphamide Treatment for Steroid-resistant Interstitial Pneumonitis Associated with Polymyositis","volume":"38","author":"Yoshida","year":"1999","journal-title":"Intern. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: A systematic review","volume":"34","author":"Ge","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_85","first-page":"1","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/14397595.2013.874762","article-title":"Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis","volume":"24","author":"Tsuchiya","year":"2014","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Allenbach, Y., Guiguet, M., Rigolet, A., Marie, I., Hachulla, E., Drouot, L., Jouen, F., Jacquot, S., Mariampillai, K., and Musset, L. (2015). Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: An open-label, phase II trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133702"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease\u2013associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","article-title":"Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan","volume":"56","author":"Tokunaga","year":"2017","journal-title":"Intern. Med."},{"key":"ref_92","first-page":"1","article-title":"Effective Administration of Rituximab in Anti-MDA5 Antibody\u2013Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review","volume":"2017","author":"Ogawa","year":"2017","journal-title":"Case Rep. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): Study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","article-title":"Interleukin-18 is a key mediator in dermatomyositis: Potential contribution to development of interstitial lung disease","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report","volume":"99","author":"Ishikawa","year":"2020","journal-title":"Medicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.60.6.635","article-title":"Intravenous gammaglobulins in refractory polymyositis: Lower dose for maintenance treatment is effective","volume":"60","author":"Genevay","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV Immunoglobulin Might Be Considered as a First-line Treatment of Severe Interstitial Lung Disease Associated with Polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"key":"ref_103","first-page":"1682","article-title":"Intravenous Immunoglobulin as Potential Adjunct Therapy for Interstitial Lung Disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/1744-9987.12939","article-title":"Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis","volume":"24","author":"Abe","year":"2020","journal-title":"Ther. Apher. Dial."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jca.21833","article-title":"Anti-MDA -5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series","volume":"36","author":"Saito","year":"2021","journal-title":"J. Clin. Apher."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology"},{"key":"ref_108","first-page":"586","article-title":"Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis\/dermatomyositis","volume":"59","author":"Watanabe","year":"2019","journal-title":"Rheumatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis\/Dermatomyositis\u2013Associated Interstitial Lung Disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/4\/347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:58:18Z","timestamp":1760363898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/4\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,3]]},"references-count":110,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["medicina57040347"],"URL":"https:\/\/doi.org\/10.3390\/medicina57040347","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,3]]}}}